Best Life Sciences Rush Hour Inve Podcasts (2025)

1
Where does the market go from here? Will retail investors sell? 9:21

6+ y ago9:21

9:21

We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medtronic’s settlement and how insurance could have been implemented to reduce the financial burden for Medtronic.…

1
What’s the deal with GE? 8:34

6+ y ago8:34

8:34

GE has seen its market cap decrease by over $200B since 2016 and it now trades at around $8. Is this the correct value or should it be higher or perhaps lower?

1
We changed our name and Amazon announced their new locations! 10:31

6+ y ago10:31

10:31

Why we changed our name to the MattCorc Podcast. Who is taking the most risk with the Amazon headquarters, Amazon or the local/state government? What is Waymo? The first autonomous ride hailing service is getting ready to launch in Arizona.

1
A $500 Million Biotech IPO. Amarin Data 9:04

6+ y ago9:04

9:04

Moderna plans the biggest biotech IPO ever and we learn more about Amarin’s clinical study. Was mineral oil the best choice of placebo? Lessons we can learn from Amarin about D&O insurance.

1
Herd Mentality. Why D&O benchmarking is a sales ploy. What to use to make a more informed decision. 9:14

6+ y ago9:14

9:14

I talk about how brokers use benchmarking to sell you more D&O insurance. Brokers take advantage of herd mentality so insurers buy more D&O than they need.

1
Why cost should only be one consideration 5:24

6+ y ago5:24

5:24

Cost and its importance are discussed. Minor differences in coverage can cause major headaches when you have a claim.

1
S&P Companies not as negative; Gene Therapy manufacturing is stretched thin 7:21

6+ y ago7:21

7:21

Happy national doughnut day! Fewer companies in the S&P are providing negative guidance. What does this mean? How CFOs are protecting their balance sheets in the event their manufacturing is disrupted.

1
Lessons from Halloween when your kids have peanut allergies 8:56

6+ y ago8:56

8:56

Why is Aimmune (AIMT) up today? Is it because Halloween reminded investors how many types of candy have peanuts in them? A lesson on how to make sure you aren’t missing significant coverage gaps in your insurance program. Hint: I learned it from checking my kids Halloween candy.

1
Swimming and the Dow Jones 5:09

6+ y ago5:09

5:09

How my first time swimming in a lap pool in years was a good metaphor for today’s market and some other interesting facts on the financial markets.

1
President’s Drug Pricing Speech and New CA Sexual Harassment Law 8:49

6+ y ago8:49

8:49

An overview of the President’s drug pricing proposal and what the new California sexual harassment law could mean for your insurance.

1
M&A Activity - Will Market Forces Play a Role? 3:28

6+ y ago3:28

3:28

With biotech stocks sinking, the XBI just hit a 52 week low, and interest rates rising will we see an urgency for acquisitions to be done?

1
Episode 36 - Concept or Concrete? 2:09

6+ y ago2:09

2:09

Quick post on why Insurance buying doesn’t need to be so abstract.

1
Episode 35 - McDermott Will & Emery Dealmaking Symposium Recap 9:57

6+ y ago9:57

9:57

A ton was learned at the MWE life science deal making symposium and here I share that with you.

1
Episode 34 - DeviceTalks Recap 7:39

6+ y ago7:39

7:39

A synopsis of DeviceTalks Boston. Pathways to acquisition, hurdles that you might face and how to derisk your company to make it more appealing to investors and acquiring companies.

1
Episode 33 - Chinese Espionage and Cyber Coverage 6:17

6+ y ago6:17

6:17

What can we learn from the alleged Chinese cyber espionage incident and how cyber insurance could respond.

1
Episode 32 - Can the Biotech IPO Market Sustain Itself? 5:35

6+ y ago5:35

5:35

I would love to hear whether people believe the pace of biotech IPOs will continue. Hear my thoughts and share yours at mattcorc.com.

1
I’m Doing an IPO and My D&O Insurance is Expensive 8:03

6+ y ago8:03

8:03

Why D&O Insurance is expensive for life science companies and how the stage your company is in impacts pricing.

1
FDA Condemns Undamaged Product - Insurance Should Have Paid 5:16

6+ y ago5:16

5:16

A client had a fire and $250,000 in product was destroyed. Undamaged condemned stock was valued at over $500,000 but there insurance did not cover it. Find out why that should never happen.

1
Episode 29 - MD Bio-Tech Conference Recap 11:28

6+ y ago11:28

11:28

A recap of the Maryland Bio-Tech Conference that I recently attended.

1
Episode 28 - NJTC CFO Forum Recap 10:20

6+ y ago10:20

10:20

A recap of the CFO Forum put on by the NJ Tech Council. The speaker was Jim Mastakas who was the CFO of Amneal when they merged with Impax Labs

1
Episode 27 - Monday Market Update 7:50

6+ y ago7:50

7:50

The impacts of Hurricane Florence on the property insurance market are discussed

1
Common Question Friday #1 6:37

6+ y ago6:37

6:37

Why does a pre-clinical company need insurance?

1
Apple Watch, Transitioning From Digital Health to Med Device 5:36

6+ y ago5:36

5:36

A quick synopsis of how insurance liability changes as a company enters the realm to an FDA regulated product.

1
Hurricane Florence and Where to Look for Property Coverage 9:19

6+ y ago9:19

9:19

Where to look for additional coverage in your proprty policy above and beyond replacing your building or contents. Things to be aware of that could reduce coverage.

1
Abbvie Testosterone Settlement and Product Liability 10:26

6+ y ago10:26

10:26

I discuss the Abbvie testosterone settlement and the role of product liability insurance could play. Hurricanes and property insurance.

1
Episode 22 - Boston Biotech Week and RESI 8:47

6+ y ago8:47

8:47

A recap of Boston Biotech Week and the RESI conference. How insurance can help you stand out with investors.

1
Episode 21 - Patent Insurance...It’s a Real Thing 9:29

7y ago9:29

9:29

An overview of patent insurance and what it can do.

1
Episode 20 - Opioid Settlement and Product Liability 10:27

7y ago10:27

10:27

A discussion on Product Liability insurance in relation to a possible opioid settlement. Wage & Hour lawsuits are on the rise but there is a solution.

1
What happens when your supply chain is disrupted? 7:17

7y ago7:17

7:17

In the wake of an API manufacturer being shut down in China I discuss using insurance to mitigate the cash flow disruption.

1
Should Public Companies Only Report Earnings Semi-Annually? 7:55

7y ago7:55

7:55

The possible impacts on moving from quarterly to semiannual reporting periods for public companies on the D&O insurance marketplace

1
Episode 17 - Getting Your Product Approved 10:28

7y ago10:28

10:28

Amicus and Alnylam both got FDA approval last week. Find out how that can change their risk profile.

1
Cyber Insurance - Is Change Coming? 7:49

7y ago7:49

7:49

I discuss the PGA Championship being cyber extorted, CA Consumer Privacy Act and the role insurance plays in both of these events.

1
Apple, AIG, D&O Insurance and Patents 10:53

7y ago10:53

10:53

We discuss Apple hitting the $1 trillion mark, AIG going the other way, government taking your patent and D&O insurance

1
Episode 14 - Securities Class Action Filings and D&O Cover 8:09

7y ago8:09

8:09

I talk about the prevalence of securities class action filings and how D&O can protect you. I also discuss how we should not choose limits solely by what our peers have in place.